Atrial Fibrillation After Cancer: Why It Is Common and What Changes About Treatment
AF is more frequent after cancer treatment and the usual decisions are harder, because bleeding risk, platelet counts, and drug interactions all sit alongside stroke prevention. What survivors and their clinicians need to weigh.
Atrial fibrillation is more common after cancer than in the general population of the same age, and the standard decisions around it are harder. Stroke prevention still matters, but bleeding risk, platelet counts, and drug interactions all sit in the same conversation.
Why AF turns up more often after cancer
Thoracic surgery, chest radiation, inflammation, electrolyte disturbance, and several systemic therapies including some kinase inhibitors all raise the chance of atrial fibrillation. Age and shared risk factors such as hypertension add to it. Some episodes are transient and tied to an acute illness; others persist.
Because the sensation can be mild, AF in survivors is often found incidentally. That is a good reason to check the pulse at every survivorship review rather than only when someone complains.
Confirming it properly
An irregular pulse needs a formal recording. A twelve-lead trace captures it if it is present at the time; otherwise an ambulatory monitor or a longer wearable patch is used. Consumer wearables are useful for flagging a pattern but are not a diagnosis on their own, and a clinician still needs to see a proper trace.
Once confirmed, check thyroid function, electrolytes, haemoglobin, and blood pressure, and review current cancer therapies for known rhythm effects.
Stroke prevention when bleeding risk is not standard
Conventional stroke risk scores were not developed in people with cancer, and anticoagulation decisions here also involve platelet count, tumour site and bleeding tendency, renal and hepatic function, and interactions with systemic therapy. Some anticoagulants interact meaningfully with kinase inhibitors and azole antifungals.
The practical answer is a documented, shared decision between cardiology and oncology, reviewed whenever treatment changes, rather than a one-off calculation applied indefinitely.
Rate, rhythm, and symptoms
Rate control is often the first step, with beta blockade or a dihydropyridine-sparing choice depending on ventricular function and interactions. Rhythm control is considered for persistent symptoms or where AF is driving heart failure. Any strategy should be revisited after active cancer therapy ends, because the drivers may have resolved.
Report worsening breathlessness, chest pain, fainting, or a sustained fast rate promptly rather than waiting for the next scheduled review.
Frequently asked questions
- Is atrial fibrillation more common in cancer survivors?
- Yes. Thoracic surgery, chest radiation, inflammation, electrolyte disturbance, and several systemic therapies raise the risk, on top of age and shared risk factors such as hypertension.
- Can survivors take blood thinners for atrial fibrillation?
- Often yes, but the decision must weigh platelet count, tumour bleeding risk, renal and hepatic function, and interactions with cancer therapy, and it should be reviewed whenever treatment changes.